Truvestments Capital LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 4.1% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 22,300 shares of the company’s stock after buying an additional 880 shares during the quarter. Johnson & Johnson makes up about 1.9% of Truvestments Capital LLC’s holdings, making the stock its 7th biggest position. Truvestments Capital LLC’s holdings in Johnson & Johnson were worth $2,885,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently bought and sold shares of JNJ. Virtus ETF Advisers LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth $25,000. Krane Funds Advisors LLC bought a new stake in Johnson & Johnson during the 2nd quarter valued at $26,000. Crewe Advisors LLC grew its stake in shares of Johnson & Johnson by 725.9% in the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock worth $31,000 after acquiring an additional 196 shares in the last quarter. Permanens Capital L.P. grew its stake in shares of Johnson & Johnson by 50.0% in the 2nd quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock worth $42,000 after acquiring an additional 100 shares in the last quarter. Finally, Thor Advisors LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter worth $69,000. 72.01% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NYSE:JNJ traded up $2.76 during midday trading on Friday, reaching $131.82. The company had a trading volume of 1,750,647 shares, compared to its average volume of 6,702,304. The company’s 50 day moving average price is $129.92 and its 200 day moving average price is $135.00. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46. The stock has a market cap of $347.95 billion, a P/E ratio of 16.11, a P/E/G ratio of 2.22 and a beta of 0.69. Johnson & Johnson has a 52-week low of $121.00 and a 52-week high of $148.99.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.42 by $0.16. The company had revenue of $20.56 billion for the quarter, compared to the consensus estimate of $20.39 billion. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The firm’s quarterly revenue was down 1.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.10 EPS. Research analysts forecast that Johnson & Johnson will post 8.59 EPS for the current fiscal year.
Several analysts have recently issued reports on the stock. Morgan Stanley reiterated an “equal weight” rating and issued a $145.00 target price on shares of Johnson & Johnson in a research note on Tuesday, August 27th. Bank of America reiterated a “hold” rating and issued a $150.00 target price on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Goldman Sachs Group set a $169.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Finally, Raymond James reduced their target price on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating for the company in a research note on Wednesday, July 17th. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $151.00.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: How is net asset value different from market price?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.